Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Not Yet Recruiting

Trial opening soon.

Key information

Conditions

Diabetic Nephropathies Diabetes Complications Diabetes Mellitus Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Urogenital Diseases Urologic Diseases

Age range

30 year–75 year

Sex eligibility

All sexes

Study type

Observational

About this study

Diabetes is a prevalent worldwide challenge affecting 425 million individuals, with the International Diabetes Federation (IDF) projecting a rise to 630 million by 2045. Diabetic nephropathy (DN) is a critical complication that impacts one-third of diabetic patients and significantly contributes to cardiovascular morbidity and mortality, leading to substantial socioeconomic burdens (Dwivedi and Sikarwar, 2024).

Diabetic nephropathy (DN) is a multifaceted condition involving various interconnected mechanisms, primarily influenced by hyperglycemia .

Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD).

Therefore, early recognition is crucial. Presently, this relies on the albumin excretion rate (AER) and glomerular filtration rate (GFR).

Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear.

Experimental studies have demonstrated the role of irisin in protecting mice against diabetes and obesity

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type 2 diabetic patients

Exclusion criteria

Non-diabetic kidney diseases.
Acute illness, infection, obesity, hypertension, type 1 DM.
Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.

Treatment and study plan

HBA1C

Diagnostic Test

Rapid method for detection of diabetes

glucose

Diagnostic Test

accurate method for diabetes

Primary outcomes

Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Time frame: Two years

Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Study contacts

Contact information is provided by the study sponsor or research team.

Gehad Ha Abdelmegid, MD

CONTACT

[email protected]

00201125745717

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2028
First posted: Feb 27, 2026
Registry last updated: Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting